

ANIKA THERAPEUTICS INC  
Form 8-K  
March 05, 2008  
UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 5, 2008

Anika Therapeutics, Inc.  
*(Exact name of registrant as specified in its charter)*

Massachusetts                      000-21326                      04-314-5961  
*(State or other jurisdiction of    Commission file number    (I.R.S. Employer*  
*incorporation or organization)                      Identification No.)*

32 Wiggins Avenue, Bedford, MA 01730  
*(Address of principal executive offices) (Zip code)*

*Registrant's telephone number, including area code: (781) 457-9000*

*(Former name or former address, if changed since last report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Section 2--Financial Information**

Item 2.02. Results of Operations and Financial Condition.

The following information, including the exhibit attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

On March 5, 2008, Anika Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2007. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

**Section 9--Financial Statements and Exhibits**

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release of Anika Therapeutics, Inc. dated March 5, 2008.

[Remainder of page left blank intentionally]

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Anika Therapeutics, Inc.

Date: March 5, 2008 By: /s/ Kevin W. Quinlan  
Kevin W. Quinlan  
Chief Financial Officer

---

EXHIBIT INDEX

99.1 Press Release of Anika Therapeutics, Inc. dated March 5, 2008.